Department of Surgery, Kusatsu General Hospital, 1660 Yabase-Cho, Shiga, Kusatsu City 5258585, Japan.
Gastroenterol Res Pract. 2012;2012:741202. doi: 10.1155/2012/741202. Epub 2012 Aug 21.
Background. Patients with early stage of pseudomyxoma peritonei (PMP) are sometimes difficult to diagnose the primary sites and intraperitoneal spread of tumor and to perform a cytological study. Methods. Patients without a definitive diagnosis and with unknown extent of peritoneal spread of tumor underwent laparoscopy. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) was administered as part of the same intervention. The results of treatment were evaluated at the time of second-look laparotomy (SLL) as a subsequent intervention. Results. Eleven patients were managed by diagnostic laparoscopy followed by laparoscopic HIPEC (LHIPEC). The operation time of laparoscopic examination and LHIPEC was 177 ± 26 min (range 124-261 min). No intraoperative complication was experienced. The peritoneal carcinomatosis index (PCI) score by laparoscopic observation was 16.5 ± 6.4 (range 0-30). One patient with localized pseudomyxoma peritonei (PMP) mucocele did not received LHIPEC; the other 10 patients with peritoneal metastases (PM) were treated with LHIPEC. After LHIPEC, ascites disappeared in 2 cases and decreased in the amount in the other 8 cases. Nine patients underwent SLL and cytoreductive surgery (CRS) combined with HIPEC. The duration between LHIPEC and SLL ranged from 40 to 207 days (97 ± 40 days). The PCI at the SLL ranged from 4 to 27 (12.9 ± 7.1). The PCI at the time of SLL decreased as compared to PCI at the time of diagnostic laparotomy in 7 of 9 patients. Median follow-up period is 22 months (range 7-35). All 11 patients are alive. Conclusion. The early results suggest that laparoscopic diagnosis combined with LHIPEC is useful to determine the surgical treatment plan and reduce the tumor burden before definitive CRS at SLL.
背景。对于早期的假性黏液瘤腹膜病(PMP)患者,有时难以诊断原发部位和肿瘤的腹腔内播散,并进行细胞学研究。方法。对于没有明确诊断且肿瘤腹腔播散程度未知的患者,进行腹腔镜检查。术中腹腔高温化疗(HIPEC)作为同一干预措施的一部分进行。在二次探查腹腔镜手术(SLL)作为后续干预时,评估治疗结果。结果。11 名患者接受了诊断性腹腔镜检查,然后进行腹腔镜 HIPEC(LHIPEC)。腹腔镜检查和 LHIPEC 的手术时间为 177±26 分钟(范围 124-261 分钟)。术中无并发症。腹腔镜观察的腹膜癌指数(PCI)评分为 16.5±6.4(范围 0-30)。1 例局限性假性黏液瘤腹膜病(PMP)黏液囊肿患者未接受 LHIPEC;其余 10 例腹膜转移(PM)患者接受 LHIPEC 治疗。LHIPEC 后,2 例腹水消失,8 例腹水减少。9 例患者接受 SLL 和细胞减灭术(CRS)联合 HIPEC。LHIPEC 与 SLL 之间的时间间隔为 40-207 天(97±40 天)。SLL 的 PCI 范围为 4-27(12.9±7.1)。9 例患者中,7 例患者的 SLL PCI 较腹腔镜检查时 PCI 降低。中位随访时间为 22 个月(范围 7-35)。11 例患者均存活。结论。早期结果表明,腹腔镜诊断联合 LHIPEC 有助于确定手术治疗方案,并在 SLL 时进行确定性 CRS 前降低肿瘤负荷。